CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Combination of azelaic acid 5 and erythromycin 2 in the treatment of acne vulgaris
Authors
M. Ajami
S. Babakoohi
+7 more
A. Firooz
R. Habibey
M. Nassiri-Kashani
H. Pazoki-Toroudi
M. Rahshenas
M. Shizarpour
H. Tabatabaie
Publication date
1 January 2010
Publisher
Abstract
Introduction: Acne vulgaris is a common problem, particularly among adolescents, which is usually resistant to monotherapy. We evaluated the efficacy and safety of a combination of azelaic acid (AA) 5 and erythromycin 2 gel (AzE) compared with AA 20 or erythromycin 2 gels in facial acne vulgaris.Methods: We conducted a 12-week, multicenter, randomized double-blind study on 147 patients with mild-to-moderate acne vulgaris. Four treatment group were determined (placebo, erythromycin, AA and AzE) and followed in 4-week intervals for 12 weeks, except the placebo group which was changed to routine treatment after 4 weeks.Results: The combination of AA 5 and erythromycin 2 gel significantly reduced the number of papules, pustules and comedones compared with placebo (p <0.001), erythromycin 2 (p <0.01) or AA 20 (p <0.05). The incidence of adverse effects observed in patients treated with AzE (27) was less than that with erythromycin 2 (54) and AA 20 (45).Conclusions: The combination of AA 5 and erythromycin 2 produced more potent therapeutic effects in comparison with erythromycin 2 or AA 20 alone, and with fewer side effects. © 2010 Informa UK Ltd
Similar works
Full text
Available Versions
eprints Iran University of Medical Sciences
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:eprints.iums.ac.ir:21275
Last time updated on 21/02/2021